Dendrimer-Based Drug Delivery

When: Friday, November 18, 2011 at 12:00 pm
Where: DG 130
Speaker: Dr. Lajos Balogh
Organization: Professor of Pharmaceutical Sciences Northeastern University (Adjunct), Editor-in-Chief at Nanomedicine: Nanotechnology, Biology, and Medicine (Elsevier)
Sponsor: IGERT

The nanotechnology drug delivery market is expected to grow at a CAGR of 21.7% for the period 2009-2014. The healthcare nanotechnology market growth is largest in North America, at $4.75bn in 2009, followed by Europe at $3.65. In 2010, nanotechnology in drug delivery the targetable market represented 1347 m USD, of which dendrimers (84 M $) were second only to lipsomes (118M$).

Most traditional drugs are not complex enough to affect multiple intracellular processes simultaneously. To achieve that goal, multifunctional nanodevices must be used that are assembled from various synthetic components each designed to carry out a desired function. This approach requires a flexible and tunable platform that holds together all the primary components. Dendrimers are symmetrically branching synthetic macromolecules that display properties of not only a multifunctional polymer, but also an organic nanoparticle. Due to this unique combination of chemical and materials properties, dendrimers can be used as a platform to construct multifunctional nanodevices. Dendrimers can be synthesized in various chemical compositions, in discrete sizes, and with multiple (and variable) surface functionalities. The assembled nanodevices are able to target specific cells, tissues, and organs and deliver imaging agents and drugs. In this lecture, essential properties of dendrimers will be explained on polyionic dendrimers, the most significant dendrimer family for drug delivery. Among others, basic concepts of forming a delivery device, pharmacokinetics, and drug release will be elucidated using both research and practical examples.